Thorsten Waloschek/LinkedIn
Dec 21, 2025, 02:24
Thorsten Waloschek: New Study Highlights Preeclampsia Risk Stratification Benefits
Thorsten Waloschek, CEO of NeoPredics AG, shared a post on LinkedIn:
“This is an important signal for maternal health innovation in pregnancy.
A large new study shows that identifying women at higher risk of preeclampsia late in pregnancy, and acting on that risk with planned early-term birth, reduced term preeclampsia by around 30%.
Risk stratification, biomarkers, and structured decision-making during pregnancy can change outcomes – even without new drugs. This reinforces how much potential still sits in smarter diagnostics and data-driven pathways to protect mothers’ cardiovascular health during pregnancy.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Oct 14, 2026, 15:25Beyond Embryo Morphology: Can 2 Embryos Influence Each Other’s Implantation Through Endometrial Crosstalk?
-
Oct 14, 2026, 15:01Nitiz Murdia: 5,000 Indian Rupees and a 2-Room Fertility Clinic in 1988…
-
Oct 14, 2026, 14:58Devyanshi Dixit։ Can We Measure Ovarian Age?
-
Oct 14, 2026, 14:56Rohit Gutgutia: The IVF Price War, and Who Really Pays for It
-
Oct 14, 2026, 14:54Abdullah F. Edrees։ Marking an Important Milestone for IVF
-
Oct 14, 2026, 14:50Gregory Poulos: Pleased to Be Named President of Vios Fertility 2.0
-
Oct 13, 2026, 16:58Slavian Bumbu: A Low AMH Is Not an Infertility Diagnosis
-
Oct 13, 2026, 16:43Keshav Malhotra: No Embryologist or Laboratory Technique Can Guarantee Euploid Embryos
-
Oct 13, 2026, 16:37Tony Gordon: What Is the Most Successful Form of Fertility Treatment?
